Physician profile
Ammar Qoubaitary
NPI 1851346977
$507,695.24
in general payments reported to CMS, 2019-2025
71 companies · $93K in 2025
The $93K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $43K · 2021: $88K · 2022: $79K · 2023: $48K · 2024: $46K · 2025: $93K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $149K · Food and Beverage: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Travel and Lodging: $8,242 · Consulting Fee: $1,800 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $149,046.75 |
| Food and Beverage | $15,370.67 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,750.00 |
| Travel and Lodging | $8,241.78 |
| Consulting Fee | $1,800.00 |
| Education | $268.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $301,745.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $63,533.62 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $29,428.24 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,426.30 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $23,842.82 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Dexcom, INC. | $15,270.01 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $9,465.10 | 2019-2022 | |
| Ibsa Pharma INC. | $8,868.30 | 2019-2025 | Tirosint, Tirosint, Licart |
| Amgen INC. | $8,490.95 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $8,092.05 | 2019-2025 | |
| Corcept Therapeutics | $2,278.11 | 2019-2023 | Korlym |
| Cambridge Interventional LLC | $1,312.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,054.95 | 2021-2025 | |
| Radius Health, INC. | $935.87 | 2019-2025 | Tymlos |
| Abbvie INC. | $798.52 | 2019-2025 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $626.95 | 2020-2023 | Tepezza |
| Beta Bionics, INC. | $619.59 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Mannkind Corporation | $586.15 | 2019-2025 | Afrezza |
| Abbott Laboratories | $442.48 | 2019-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $414.17 | 2019-2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $381.50 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Merck Sharp & Dohme LLC | $332.18 | 2019-2023 | Dificid |
| Pfizer INC. | $315.83 | 2020-2024 | |
| Antares Pharma, INC. | $285.96 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Biohaven Pharmaceuticals, INC. | $281.41 | 2020-2021 | |
| Medtronic, INC. | $269.15 | 2022-2025 | Minimed 780g |
| Currax Pharmaceuticals LLC | $206.29 | 2023-2025 | Contrave, Onzetra Xsail |
| Ascendis Pharma Endocrinology INC | $196.33 | 2022-2025 | Yorvipath |
| Glaxosmithkline, LLC. | $188.08 | 2023-2025 | Shingrix, Arexvy, Menveo |
| Biohaven Pharmaceutical Holding Company Ltd. | $184.49 | 2022 | |
| Madrigal Pharmaceuticals | $166.10 | 2024-2025 | Rezdiffra |
| Allergan, INC. | $134.69 | 2021 | |
| Bausch Health US, LLC | $105.38 | 2022-2024 | Aplenzin |
| Insulet Corporation | $99.75 | 2019-2025 | Omnipod |
| Esperion Therapeutics, INC. | $87.12 | 2020 | |
| Embecta Corp. | $86.43 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Halozyme INC | $68.59 | 2023 | |
| Shire North American Group INC | $63.32 | 2019 | |
| Ascensia Diabetes Care US INC. | $63.29 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $60.39 | 2019-2023 | Evkeeza |
| Tandem Diabetes Care, INC. | $59.02 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Exact Sciences Corporation | $57.65 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $52.18 | 2019-2020 | |
| Averitas Pharma INC. | $50.66 | 2023-2024 | Qutenza |
| Astellas Pharma US INC | $42.66 | 2024-2025 | Veozah |
| Acella Pharmaceuticals, LLC | $40.12 | 2023-2025 | NP Thyroid 60 |
| Agios Pharmaceuticals, INC. | $38.40 | 2025 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $35.52 | 2020-2023 | Trintellix |
| Grt US Holding, INC. | $30.57 | 2021 | |
| Amryt Pharma Holdings Ltd | $30.06 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.54 | 2024 | Rexulti |
| Companion Medical, INC. | $29.00 | 2019 | |
| Neurocrine Biosciences, INC. | $28.59 | 2025 | |
| Novartis Pharmaceuticals Corporation | $26.71 | 2025 | |
| Sequel Med Tech, LLC | $25.73 | 2025 | Twiist |
| Dynavax Technologies Corporation | $24.84 | 2024 | Heplisav-B |
| Kyowa Kirin, INC. | $24.05 | 2024 | Crysvita |
| Almatica Pharma LLC | $24.02 | 2024 | Teriparatide |
| Senseonics, Incorporated | $24.00 | 2019 | |
| Endo Pharmaceuticals INC. | $22.73 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $22.25 | 2023 | Prehevbrio |
| Impel Pharmaceuticals INC. | $21.95 | 2022 | |
| Mayne Pharma Commercial LLC | $21.46 | 2025 | |
| Lifescan, INC. | $20.16 | 2020 | |
| Cequr Corporation | $19.43 | 2022 | |
| Mylan Pharmaceuticals INC. | $19.21 | 2021 | |
| Phadia US INC. | $19.17 | 2024 | Immunocap |
| Bigfoot Biomedical INC | $15.61 | 2021 | |
| Lundbeck LLC | $13.14 | 2024 | Rexulti |
| Clarus Therapeutics INC. | $11.83 | 2021 | |
| Janssen Scientific Affairs, LLC | $6.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Qoubaitary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.